An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High (≥50% Of Tumor Cel Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.

drug protocol number
C5751003
drug sponsor
Pfizer
drug study
Sigvotatug Vedotin and Pembrolizuma
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase